Aizant Overview

  • Founded

  • 2005

Founded
  • Status

  • Private

  • Employees

  • 658

Employees
  • Latest Deal Type

  • PE Growth

  • Financing Rounds

  • 3

Aizant General Information

Description

Provider of integrated drug development services intended to partner with international and domestic pharmaceutical companies in new molecular entities (NME's), generics (ANDA's) and over-the-counter (OTC's) products. The company is engaged in the formulation, development and clinical research services for conventional and novel drugs, thereby helping clients in their research and development programs at every stage from the discovery of the molecule to commercialization and subsequent life cycle management.

Contact Information

Website
www.aizant.com
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Sy No. 172 & 173, Apparel Park Road
  • Dulapally, Quthbullapur Mandal
  • Hyderabad, Telangana 500100
  • India
+91 040 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aizant Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aizant‘s full profile, request access.

Request a free trial

Aizant Patents

  • 11

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Aizant Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3179353-A1 Coated chewing gum compositions Pending 03-Apr-2020 00000000
US-20200316025-A1 Stable amorphous eliglustat premix and process for the preparation thereof Pending 20-Dec-2017 00000000000
EP-3687539-A1 Stable pharmaceutical compositions of dalfampridine Inactive 25-Sep-2017 0000000000
EP-3687539-A4 Stable pharmaceutical compositions of dalfampridine Inactive 25-Sep-2017 0000000000
CA-3021752-A1 Nanoparticulate ivacaftor formulations Inactive 11-Jun-2015 A61K31/47
To view Aizant’s complete patent history, request access »

Aizant Executive Team (3)

Name Title Board Seat Contact Info
Sridevi Sayyaparaju Chief Operating Officer & Board Member
Rudraraju Varma Ph.D Chairman & Managing Director
Bithun Shal Deputy Manager - Smart Development & Quality by Design
To view Aizant’s complete executive team members history, request access »

Aizant Board Members (7)

Name Representing Role Since
000000000 00000 00 Aizant Chairman & Managing Director 000 0000
0000000 0000000000 Aizant Chief Operating Officer & Board Member 000 0000
0.0. 000000000 InvAscent Board Member 000 0000
You’re viewing 3 of 7 board members. Get the full list »

Aizant Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aizant Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aizant‘s full profile, request access.

Request a free trial